Introduction IgA nephropathy is one of the most common forms of glomerular disease.
Patients with persistent proteinuria are at increased risk of progression to kidney failure …

IgA nephropathy (IgAN) is considered the most common primary glomerulonephritis
worldwide with a predilection for Asian-Pacific populations and relative rarity in those of …

We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of
patients with IgA Nephropathy. We conducted a prospective, interventional, open-label …

Background: IgA nephropathy (IgAN), a condition posing a significant threat to public health,
currently lacks a specific treatment protocol. Research has underscored the potential …

IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response
to aberrant glycosylated immunoglobulin (Ig) A antibodies. Although it has historically been …

Immune checkpoint inhibitors (ICIs) dramatically improve the prognosis of many
malignancies but at the cost of numerous side effects, which may limit their benefits. Acute …

Introduction CM313 is currently under clinical investigation for treatments of multiple
myeloma, systemic lupus erythematosus, and immune thrombocytopenia. We aimed to …

The Oxford histopathologic classification (MEST-C: scores for lesions indicating active
glomerular inflammation, mesangial [M] and endocapillary [E] hypercellularity as well as …

Background The effects of tonsillectomy combined with steroid pulse (TSP) therapy for IgA
nephropathy (IgAN) are little known. Therefore, we examined the effects of TSP therapy on …

Introduction Nefecon, the first innovative drug approved by both the US Food and Drug
Administration (FDA) and European Medicines Agency for IgA nephropathy (IgAN), lacked …